Aim. To confirm the efficacy and tolerability of ziprasidone as adjunctive therapy in bipolar patients partially responding to clozapine or with persisting negative symptoms, overweight, or with metabolic syndrome. Methods. Eight patients with psychotic bipolar disorder were tested with the BPRS, the HAM-D, and the CGI at T0 and retested after 2 weeks (T1). Plasma clozapine and norclozapine levels and BMI were tested at T0 and T1. Results. Ziprasidone was well tolerated by all the patients. BPRS and HAM-D scores were reduced in all patients. BMI was reduced in patients with a BMI at T0 higher than 25. Plasma levels of clozapine and norclozapine showed an irregular course.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003829PMC
http://dx.doi.org/10.1155/2014/904829DOI Listing

Publication Analysis

Top Keywords

ziprasidone adjunctive
8
adjunctive therapy
8
bipolar patients
8
bprs ham-d
8
clozapine norclozapine
8
reduced patients
8
patients bmi
8
patients
6
therapy severe
4
severe bipolar
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!